Citrulline
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Citrulline: From Nutritional Amino Acid Supplement to Multiple Endocrine Neoplasia
One-Sentence Summary
Citrulline (L-citrulline) is a naturally occurring amino acid and key intermediate in the urea cycle, widely used as a nutritional supplement to support nitric oxide (NO) production and cardiovascular function — it has no formally registered therapeutic indication in Australia or in our dataset. The TxGNN model predicts it may have potential in Multiple Endocrine Neoplasia (MEN), with a prediction score of 97.00%. However, there are currently no clinical trials and no published literature directly supporting this indication, making this a model-only prediction with a high risk of false-positive.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No formally registered therapeutic indication; used as a nutritional supplement (urea cycle support, NO precursor) |
| Predicted New Indication | Multiple Endocrine Neoplasia |
| TxGNN Prediction Score | 97.00% |
| Evidence Level | L5 |
| Australia Market Status | Not marketed (no TGA registration) |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for Citrulline was not available in our dataset. Based on known biochemistry, L-citrulline is a non-essential amino acid and a central intermediate in the urea cycle. In the small intestinal enterocytes, citrulline is synthesised from glutamine and then released into circulation, where the kidneys and other tissues convert it to L-arginine. L-arginine in turn serves as the primary substrate for nitric oxide synthase (NOS), making citrulline an indirect but biologically important precursor to nitric oxide (NO) — a key signalling molecule in vascular tone, immune modulation, and cellular metabolism.
Multiple Endocrine Neoplasia (MEN) is a group of hereditary tumour syndromes driven by germline mutations in specific genes: MEN1 (a tumour suppressor affecting the parathyroid, pituitary, and pancreatic islets) and RET (an oncogene driving medullary thyroid carcinoma and phaeochromocytoma in MEN2). These genetic mechanisms operate through cell-cycle regulation and receptor tyrosine kinase signalling pathways — there is no established biological link between Citrulline’s urea cycle or NO-generating activity and the suppression or modulation of MEN tumourigenesis.
The high TxGNN score (97.00%) almost certainly reflects indirect knowledge-graph path connections — for example, shared metabolic nodes or co-occurrence patterns — rather than a direct mechanistic relationship. This is a classic false-positive risk scenario in graph-based drug repurposing models. Healthcare professionals should treat this as a computational hypothesis-generating signal only, not as clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered for Citrulline in Multiple Endocrine Neoplasia.
Literature Evidence
Currently no related literature available for Citrulline in Multiple Endocrine Neoplasia.
Australia Market Information
Citrulline (DrugBank ID: DB00155) currently has no TGA registration and is not marketed in Australia as a therapeutic product. No ARTG-listed prescription or OTC medicines containing citrulline as the active ingredient were identified. L-citrulline may be commercially available in Australia as a listed complementary medicine or sports nutrition product under a separate regulatory pathway, but no therapeutic goods registration was found.
Safety Considerations
No drug–drug interaction data was identified in our search. No key warnings or contraindications data were available from our dataset.
Please refer to the TGA-approved Product Information (PI) for safety information, or consult comparable regulatory agency documents (e.g., FDA, EMA) given the absence of Australian PI.
Conclusion and Next Steps
Decision: Hold
Rationale: Although the TxGNN model assigns a notably high prediction score (97.00%), this is entirely unsupported by clinical trials, published literature, or a credible mechanistic link — MEN is driven by specific tumour suppressor and oncogene mutations (MEN1/RET) that have no known connection to Citrulline’s metabolic pathways, and the score is most likely a knowledge-graph structural artefact.
To proceed, the following is needed:
- Obtain detailed mechanism of action (MOA) data from DrugBank API or primary pharmacology literature
- Commission a formal literature review exploring any possible interaction between nitric oxide signalling and MEN tumour biology (e.g., MEN1 cell lines, RET signalling models)
- Conduct preclinical (in vitro / in vivo) experiments to assess whether citrulline or elevated NO production affects neuroendocrine tumour growth
- Seek expert oncology and endocrinology consultation to assess biological plausibility before further investment
- Evaluate TGA registration pathways and requirements if meaningful preclinical evidence emerges
- Review comparable regulatory safety data (FDA, EMA) in the absence of an Australian PI
Disclaimer: This report is for research purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before clinical application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.